Martijn Cox, Xeltis CTO, today presented positive clinical and preclinical trial results showing that Xeltis’ electrospun polymer-based devices enable the natural restoration of complex heart parts via ETR.
Xeltis is the first company to apply pioneering electrospinning with the principles of Nobel Prize awarded supramolecular chemistry to enable cardiovascular restoration.
“These data confirm the potential of synthetic bioabsorbable polymers, without the need for stem cells, animal tissue or coating. We believe this technology represents a true paradigm shift to cardiovascular restoration strategies,” said Martijn Cox.
The 2017 Society for Biomaterials Annual Meeting is in Minnesota, USA 5-8 April. The interdisciplinary gathering strives to translate academic research to clinical practice.
Xeltis is a clinical-stage company developing synthetic medical devices that enable cardiovascular restoration.
